At week 24, a positive trend in total inflammation and total structural damage scores was observed for secukinumab treated patients compared to placebo with retrocalcaneal bursitis, peri-tendon hypersignal, and BME showing the highest mean changes.
← all excerpts
Magnetic resonance imaging characteristics in patients with spondyloarthritis and clinical diagnosis of heel enthesitis: post hoc analysis from the phase 3 ACHILLES trial.
1
—
—